Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: Role of maintenance endocrine therapy

F. Montemurro, G. Rondön, N. T. Ueno, M. Munsell, J. L. Gajewski, R. E. Champlin

    Research output: Contribution to journalArticle

    16 Scopus citations


    We retrospectively analyzed the effect of maintenance endocrine therapy (MET) after high-dose chemotherapy with hematopoietic progenitor cell transplant (HDCT) on the progression-free survival (PFS) of patients with hormone-dependent metastatic breast cancer (MBC). One hundred and nine consecutive patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive MBC, who were progression free for at least 4 months after HDCT with cyclophosphamide, carmustine and thiotepa (CBT), were analyzed. Of these, 55 were non-randomly submitted to MET. After a median follow-up of 34.4 months (17.1-91.0), univariate analysis showed that MET was significantly associated with improved median PFS (31.1 vs 19.2 months, P = 0.022). Complete response to HDCT, pattern of metastatic spread, extent of the disease, single vs multiple metastatic sites, prior endocrine therapy for metastatic disease and prior exposure to any hormonal therapy (adjuvant and/or for the advanced disease) were also associated with PFS at univariate analysis. A multivariate Cox proportional hazard model was fitted to the data in order to correct the effect of MET for the other significant covariates. After correcting for these covariates, MET was still significant, predicting improved PFS (hazard ratio (HR) 0.580, 95% CI; 0.362-0.931). Administration of MET after optimal cytoreduction might result in increased efficacy of HDCT in hormone-dependent metastatic breast cancer.

    Original languageEnglish (US)
    Pages (from-to)861-866
    Number of pages6
    JournalBone marrow transplantation
    Issue number10
    StatePublished - Jan 1 2002



    • Breast neoplasm
    • Hematopoietic stem cell transplantation
    • Hormonal therapy
    • Maintenance endocrine therapy
    • Metastatic

    ASJC Scopus subject areas

    • Hematology
    • Transplantation

    Cite this